Profile data is unavailable for this security.
About the company
Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates in two segments: bioprocess solutions and lab products and services. The bioprocess solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, filter technology for clarification, among others. The lab Products and Services segment provides instruments, consumables, and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation, and membrane filter systems for sterility testing of parenteral.
- Revenue in EUR (TTM)3.54bn
- Net income in EUR155.00m
- Incorporated1990
- Employees14.04k
- LocationSartorius AGOtto-Brenner-Str. 20GOETTINGEN 37079GermanyDEU
- Phone+49 5513080
- Fax+49 5 513083289
- Websitehttps://www.sartorius.com/
More ▼
Mergers & acquisitions
| Acquired company | SRTX:GER since announced | Transaction value |
|---|---|---|
| MatTek Corp | 15.00% | 80.00m |
Data delayed at least 15 minutes, as of Feb 18 2026 12:14 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioMerieux SA | 4.12bn | 377.90m | 10.95bn | 14.75k | 29.11 | 2.78 | 12.82 | 2.66 | 3.18 | 3.18 | 34.66 | 33.32 | 0.7715 | 1.81 | 5.96 | 279,368.30 | 6.94 | 9.22 | 8.56 | 11.94 | 56.27 | 56.58 | 8.99 | 12.35 | 1.30 | 43.19 | 0.1139 | 20.24 | 8.31 | 8.27 | 20.86 | 9.64 | 4.88 | 36.49 |
| Sonova Holding AG | 4.22bn | 570.09m | 12.84bn | 18.04k | 22.56 | 4.83 | 15.17 | 3.05 | 8.71 | 8.71 | 64.41 | 40.72 | 0.7019 | 2.42 | 7.21 | 213,874.40 | 9.62 | 10.74 | 12.57 | 13.66 | 71.66 | 72.16 | 13.71 | 17.50 | 0.9087 | 16.87 | 0.377 | 42.61 | 6.58 | 5.79 | -10.07 | 5.22 | 1.33 | -- |
| Smith & Nephew plc | 5.01bn | 414.25m | 12.86bn | 17.00k | 32.12 | 2.84 | 13.42 | 2.56 | 0.4116 | 0.4116 | 4.98 | 4.66 | 0.5599 | 0.7184 | 4.26 | 252,533.50 | 4.62 | 3.62 | 5.48 | 4.41 | 70.04 | 70.47 | 8.26 | 7.10 | 1.40 | 7.24 | 0.3842 | 87.54 | 4.70 | 2.49 | 56.65 | -7.24 | -1.36 | -2.01 |
| Coloplast A/S | 3.73bn | 533.92m | 13.64bn | 16.98k | 27.37 | 7.91 | 18.66 | 3.65 | 17.71 | 17.71 | 123.79 | 61.25 | 0.5743 | 2.38 | 6.12 | 1,625,729.00 | 8.21 | 12.75 | 10.44 | 17.10 | 67.87 | 67.86 | 14.30 | 18.95 | 0.8122 | 9.75 | 0.6451 | 100.37 | 3.12 | 8.49 | -28.03 | -2.83 | 8.92 | 5.02 |
| Sartorius AG | 3.54bn | 155.00m | 15.27bn | 14.04k | 81.16 | 4.65 | 23.47 | 4.32 | 2.24 | 2.24 | 51.24 | 39.20 | 0.357 | 2.41 | 12.72 | 251,965.50 | 2.33 | 5.04 | 3.27 | 7.04 | 46.26 | 48.75 | 6.52 | 11.14 | 0.4951 | 3.07 | 0.5255 | 23.33 | 4.66 | 8.66 | 84.40 | -5.91 | 12.96 | 0.8428 |
| Sartorius Stedim Biotech SA | 2.97bn | 265.80m | 16.61bn | 10.10k | 62.73 | 4.06 | 28.44 | 5.60 | 2.72 | 2.72 | 30.39 | 42.04 | 0.3655 | 2.36 | 12.94 | 293,870.10 | 3.28 | 6.74 | 3.85 | 8.13 | 45.33 | 48.14 | 8.97 | 13.76 | 0.5313 | 3.91 | 0.3865 | 21.88 | 6.74 | 9.21 | 51.68 | -4.59 | 19.82 | 0.2924 |
| Straumann Holding AG | 2.83bn | 468.84m | 16.83bn | 11.95k | 35.93 | 7.47 | 26.34 | 5.96 | 2.68 | 2.47 | 16.15 | 12.90 | 0.7378 | 1.72 | 4.23 | 218,270.60 | 12.29 | 12.06 | 16.00 | 15.54 | 71.24 | 74.11 | 16.65 | 17.39 | 1.13 | 10.42 | 0.1743 | 32.23 | 9.98 | 9.42 | 2.11 | 8.35 | 2.28 | 10.56 |
Data as of Feb 18 2026. Currency figures normalised to Sartorius AG's reporting currency: Euro EUR
4.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.22m | 3.27% |
| BN & Partners Capital AGas of 28 Nov 2025 | 102.69k | 0.27% |
| Carmignac UK Ltd.as of 31 Dec 2025 | 81.82k | 0.22% |
| APG Asset Management NVas of 31 Dec 2024 | 69.43k | 0.19% |
| Asset Management One Co., Ltd.as of 17 Dec 2024 | 28.60k | 0.08% |
| Keskin�inen El�kevakuutusyhti� Ilmarinenas of 31 Dec 2023 | 20.01k | 0.05% |
| Guardians of New Zealand Superannuationas of 30 Jun 2025 | 11.98k | 0.03% |
| KBC Asset Management NVas of 30 Jun 2025 | 9.20k | 0.03% |
| Fineco Asset Management DACas of 30 Jun 2025 | 8.85k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 3.00k | 0.01% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
